Synergistic combination of a phenolic-rich maple syrup extract and an antibiotic

US10206906B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10206906-B2
Application numberUS-201615159980-A
CountryUS
Kind codeB2
Filing dateMay 20, 2016
Priority dateMay 22, 2015
Publication dateFeb 19, 2019
Grant dateFeb 19, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

It is provided an anti-microbial composition comprising a phenolic-rich extract such as a phenolic-rich maple syrup extract (PRMSE) and at least one antibiotic and a method of treating a bacterial infection comprising administering to a subject in need thereof a phenolic-rich extract and at least one antibiotic.

First claim

Opening claim text (preview).

What is claimed is: 1. An anti-microbial composition with synergistic effect comprising a phenolic-rich maple syrup extract and at least one antibiotic. 2. The composition of claim 1 , wherein the at least one antibiotic is a fluoroquinolone antibiotic, a β-lactam antibiotic, aminoglycoside, polyketides, glycopeptides, benzenoids, macrolides, ansamycins, sulfonamides, chloramphenicol, oxazolidinones, carboxylic acids antibiotic, organic phosphonic acids antibiotic, quinolones and their derivatives. 3. The composition of claim 1 , wherein the at least one antibiotic is at least one of ciprofloxacin, carbenicillin, ampicillin, penicillin, kanamycin, gentamycin, tetracycline, levofloxacin, trimethoprim, sulfamethoxazole, norfloxacin, nitrofurantoin, fosfomycin, azithromycin, minocycline, am ikacin, cephalosporin, erythromycin, daptomycin, vancomycin and their derivatives. 4. The composition of claim 1 , wherein the phenolic-rich maple syrup extract is from Acer nigrum, Acer lanum, Acer acuminatum, Acer albopurpurascens, Acer argutum, Acer barbinerve, Acer buergerianum, Acer caesium, Acer campbellii, Acer campestre, Acer capillipes, Acer cappadocicum, Acer carpinifolium, Acer caudatifolium, Acer caudatum, Acer cinnamomifolium, Acer circinaturn, Acer cissifolium, Acer crassum, Acer crataegifolium, Acer davidii, Acer decandrum, Acer diabolicum, Acer distylum, Acer divergens, Acer erianthum, Acer erythranthum, Acer fabri, Acer garrettii, Acer glabrum, Acer grandidentatum, Acer griseum, Acer heldreichii, Acer henryi, Acer hyrcanum, Acer ibericum, Acer japonicum, Acer kungshanense, Acer kweilinense, Acer laevigatum, Acer laurinum, Acer lobelii, Acer lucidum, Acer macrophyllum, Acer mandshuricum, Acer maximowiczianum, Acer miaoshanicum, Acer micranthum, Acer miyabei, Acer mono, Acer mono×, Acer truncatum, Acer monspessulanum, Acer negundo, Acer ningpoense, Acer nipponicum, Acer oblongum, Acer obtusifolium, Acer oliverianum, Acer opalus, Acer palmatum, Acer paxii, Acer pectinatum, Acer pensylvanicum, Acer pentaphyllum, Acer pentapomicum, Acer pictum, Acer pilosum, Acer platanoides, Acer poliophyllum, Acer pseudoplatanus, Acer pseudosieboldianum, Acer pubinerve, Acer pycnanthum, Acer rubrum, Acer rufinerve, Acer saccharinum, Acer saccharum, Acer sempervirens, Acer shirasawanum, Acer sieboldianum, Acer sinopurpurescens, Acer spicatum, Acer stachyophyllum, Acer sterculiaceum, Acer takesimense, Acer tataricum, Acer tegmentosum, Acer tenuifolium, Acer tetramerum, Acer trautvetteri, Acer triflorum, Acer truncatum, Acer tschonoskii, Acer turcomanicum, Acer ukurunduense, Acer velutinum, Acer wardii, Acer×peronai , or Acer×pseudoheldreichii. 5. The composition of claim 1 , wherein said composition reduces biofilm formation of a bacterial strain. 6. The composition of claim 1 , wherein the anti-microbial composition is against Gram-negative or Gram-positive bacteria. 7. The composition of claim 1 , wherein the anti-microbial composition is against a bacterial strain of Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella species, Enterobacter cloacae, Burkholderia cepacia, Chromobacterium violaceum, Klebsiella pneumoniae, Helicobacter pylori, Acinetobacter baumannii, Vibrio cholera, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Legionella pneumophila, Serratia species, Shigella species, Rickettsia rickettsia, Chlamydia pneumoniae, Mycobacterium tuberculosis, Yersinia species, Moraxella catarrhalis or Proteobacteria pathogens. 8. The composition of claim 1 , wherein the extract comprises a catechol, a catechaldehyde, a gallic acid, a syringaldehyde, a vanillin, and/or a hydroxybenzoic acid. 9. The composition of claim 1 , wherein said composition represses the expression of a gene associated with multiple drug resistance, motility, virulence determinants, adhesion and/or biofilm formation. 10. The composition of claim 9 , wherein said gene associated with multiple drug resistance is emrA, acre, marC, acrA, oprM, mexA or mexX. 11. The composition of claim 9 , wherein said gene associated with motility is fliC, flhD, motB, fimH, fimA, papA2, flaA, fleQ. 12. The composition of claim 9 , wherein said gene associated with virulence determinants is chuA, cysJ, plcH, phzS or pvdA. 13. The composition of claim 9 , wherein said gene associated with adhesion is fimH, fimA, papA2, atfB, cupA1 or pelA. 14. The composition of claim 9 , wherein said gene associated with biofilm formation is uvrY, ureD or lasB. 15. A method of treating a bacterial infection comprising administering to a subject in need thereof the anti-microbial composition of claim 1 .

Assignees

Inventors

Classifications

  • Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

  • Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

  • A61K31/43Primary

    Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems · CPC title

  • Aceraceae (Maple family) · CPC title

  • Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10206906B2 cover?
It is provided an anti-microbial composition comprising a phenolic-rich extract such as a phenolic-rich maple syrup extract (PRMSE) and at least one antibiotic and a method of treating a bacterial infection comprising administering to a subject in need thereof a phenolic-rich extract and at least one antibiotic.
Who is the assignee on this patent?
The Royal Institution For The Advancement Of Learning/Mcgill Univ
What technology area does this patent fall under?
Primary CPC classification A61K31/43. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).